Charles Schwab Investment Management Inc Arcus Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 493,276 shares of RCUS stock, worth $7.51 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
493,276
Previous 472,182
4.47%
Holding current value
$7.51 Million
Previous $9.02 Million
3.27%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding RCUS
# of Institutions
186Shares Held
49.2MCall Options Held
204KPut Options Held
149K-
Black Rock Inc. New York, NY9.9MShares$151 Million0.0% of portfolio
-
State Street Corp Boston, MA4.9MShares$74.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.79MShares$73 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.88MShares$43.9 Million0.52% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$29.2 Million0.09% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.1B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...